The U.S. Food and Drug Administration (FDA) has cleared AviClear as a long-term treatment for mild to severe inflammatory acne vulgaris.

Cutera’s AviClear initially received FDA clearance for treating acne in March 2022. Now, the FDA has cleared the device for the long-term treatment of acne. This is the first acne therapy to claim long-term effectiveness for mild, moderate and severe acne, the Company states.

“It is incredibly impressive that AviClear is now the first and only acne therapy, of any kind, able to claim long-term effectiveness for mild to severe acne,” Michael H. Gold, MD, Medical Director, Gold Skin Care Center, tells DermWire. “There is nothing else on the market, not drug or laser, that can make that claim. This is huge for patients who are considering all of the treatments on the market, because they can have confidence that treatment with AviClear will also them long-term clearance.”

The first 1726nm laser to be introduced to the market, AviClear selectively targets and suppresses the sebaceous glands, eliminating acne at the source, offering a durable and prescription-free option for patients and providers. In three, 30-minute treatment sessions 90% of patients experienced visible improvement in their acne six months after their third session. According to 12-month clinical data, improvement increases to 92%, confirming long-term efficacy of acne clearance and skin quality over time.

Read more at Practical Dermatology >>